Immunology

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Opportunities For Phenotypic Screening In Drug Discovery

Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference

Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference By Dr David Suhy A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are now starting to… Read More

#Archive

#Academic #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Orphan drugs #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Reconfiguring Drug Discovery Through Innovative Partnerships

Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More

#Archive

#Academic #Analysis #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Oncology #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Cellular Raw Material Collection In Cell Therapy: Critical Determinant of Product Quality

By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. These novel biologics have potential… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microbiome #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

New Tools Bring Greater Understanding to Cellular Metabolism Research

New Tools Bring Greater Understanding to Cellular Metabolism Research By Dr John Comley The links between mitochondrial dysfunction and various diseases and pathological conditions are being increasingly revealed, such that mitochondrial analyses have gained renewed interest from both the academic research and drug discovery labs. This revival of interest in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #Lead discovery #Metabolomics #Microbiology #Molecular medicine #Oncology #Pathology #PCR #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Translational #Translational chemistry

Automating The Drive Towards Personalised Medicine

Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed, as well… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biologics / Biotechnology #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Lead optimisation #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Toxicology

Long Live Peptides – Evolution of peptide half-life extension technologies and emerging hybrid approaches

Long Live Peptides - Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Peptides, particularly those based on endogenous human… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Oncology #Pharmacology #Preclinical #RNA #Screening #System biology #Systems biology #Target validation

The Current Status of Non-Biopharma Drug Discovery

The Current Status of Non-Biopharma Drug Discovery By Dr John Comley Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Building New Models of Drug Discovery in Europe – The Innovative Medicines Initiative

Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Patent Law #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry

Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Pathology #PCR #Preclinical #Regenerative Medicine #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM)

More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM) By Dr William Bains Drug discovery in the last few decades has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and moderately successful… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays By Dr Nikolai Schwabe and Katherine Catchpole The progression from health to disease is marked by significant biological changes within an individual (1). Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analytical chemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Preclinical #Sequencing #Stem cells

The Great Neuro-Pipeline Brain Drain – Why Big Pharma Hasn’t Given Up On CNS Disorders

The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't Given Up On CNS Disorders By Julia Skripka-Serry Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry #Urinary

Evolving strategies for application-specific validation of research use antibodies

By Dr Alejandra Solache, Robert Brockett, Trinette Chuang, Dr Robin Clark, Rey Dimagiba, Dr April Fisher, Dr Wayne Speckmann and Dr Chun Yang Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Patent Law #Pharmokinetics #Regulatory #RNA #Screening #Toxicology #Translational #Translational chemistry

Highlights from GlobalData’s CRO Benchmark Report

Highlights from GlobalData’s CRO Benchmark Report By Adam M. Dion The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing sleep at night. Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More

#Archive